Sudeep Pharma Ltd
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]
- Market Cap ₹ 6,984 Cr.
- Current Price ₹ 618
- High / Low ₹ 796 / 524
- Stock P/E 73.0
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 28.6 %
- ROE 25.1 %
- Face Value ₹ 1.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.0%
Cons
- Company has high debtors of 166 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2025 | |
|---|---|
| 88 | |
| 57 | |
| Operating Profit | 31 |
| OPM % | 35% |
| 13 | |
| Interest | 2 |
| Depreciation | 2 |
| Profit before tax | 40 |
| Tax % | 25% |
| 30 | |
| EPS in Rs | 3.06 |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 218 | 345 | 404 | 344 | 357 | |
| 172 | 277 | 315 | 211 | 224 | |
| Operating Profit | 46 | 68 | 89 | 133 | 133 |
| OPM % | 21% | 20% | 22% | 39% | 37% |
| 4 | 8 | 11 | 8 | 8 | |
| Interest | 1 | 2 | 5 | 4 | 6 |
| Depreciation | 4 | 4 | 5 | 5 | 6 |
| Profit before tax | 45 | 70 | 91 | 132 | 129 |
| Tax % | 22% | 26% | 26% | 26% | 26% |
| 35 | 52 | 67 | 98 | 96 | |
| EPS in Rs | 248.31 | 371.23 | 476.69 | 696.05 | 9.85 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 23% |
| TTM: | -2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 30% |
| Last Year: | 25% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 10 | 10 |
| Reserves | 115 | 167 | 235 | 333 | 418 | 635 |
| 31 | 73 | 71 | 60 | 123 | 114 | |
| 67 | 92 | 109 | 56 | 54 | 59 | |
| Total Liabilities | 214 | 333 | 416 | 451 | 604 | 818 |
| 68 | 120 | 90 | 96 | 105 | 103 | |
| CWIP | 23 | 4 | 26 | 44 | 88 | 116 |
| Investments | 24 | 15 | 19 | 29 | 32 | 32 |
| 99 | 194 | 282 | 282 | 380 | 567 | |
| Total Assets | 214 | 333 | 416 | 451 | 604 | 818 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 36 | -5 | 42 | 59 | 59 | |
| -45 | -28 | -41 | -41 | -92 | |
| 13 | 40 | -10 | -16 | 54 | |
| Net Cash Flow | 4 | 7 | -9 | 2 | 22 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 97 | 130 | 114 | 150 | 166 |
| Inventory Days | 66 | 71 | 115 | 131 | 199 |
| Days Payable | 73 | 65 | 86 | 99 | 110 |
| Cash Conversion Cycle | 90 | 136 | 143 | 182 | 255 |
| Working Capital Days | 15 | 37 | 57 | 125 | 140 |
| ROCE % | 37% | 35% | 39% | 29% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
17h - John Garcia resigns as VP Sales & Supply Chain of Sudeep Pharma USA Inc effective COB 6 Feb 2026.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Feb
-
Board Meeting Intimation for Approval Of Unaudited Financial Results As On 31St December 2025 Along With Other Business Items
2 Feb - Board meeting 6 Feb 2026 to approve unaudited Q3/9M Dec 31, 2025 results; trading window Jan 1–Feb 8, 2026.
-
Announcement Under Regulation 30 (LODR) - Intimation Of Approval For Purchase Of Rights In Leasehold Land In GIDC By Sudeep Advanced Materials Private Limited A Wholly Owned Subsidiary (WOS) Of The Company.
22 Jan - Subsidiary acquired leasehold land in GIDC Dahej (80,980.19 sqm) for up to INR 20,97,03,000 to build battery-precursor plant.
-
General Update
16 Jan - CIN changed to L24231GJ1989PLC013141; status updated to Listed; listed on BSE/NSE 28 Nov 2025.
Concalls
-
Dec 2025Transcript PPT
Company Overview[1]
Sudeep Pharma Limited is a leading manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. The company has evolved from producing basic excipients to offering a broad portfolio of over 100 products, serving more than 1,100 customers globally. Its mineral-based ingredients, including calcium, zinc, iron, and magnesium salts, are widely used in formulations across health, nutrition, and food applications.